DUTPase inhibitors

US7795270B2 · kind B2 · utility

Assignee

• MEDIVIR AB · SE

Inventors

• Ian Gilbert · Dundee, GB
• Corinne Nguyen · Cardiff, GB
• Gian Filippo Ruda · Dundee, GB
• Alessandro Schipani · Dundee, GB
• Ganasan Kasinathan · Cardiff, GB
• Nils-Gunnar Johansson · Huddinge, SE
• Dolores Gonzalez Pacanowska · Granada, ES

Key dates

• Filing date: Jan 6, 2005
• Grant date: Sep 14, 2010
• Expiry date: Jul 30, 2027

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Deoxyuridine derivatives of the formula (I) where R1 is H or various substituents; D is —NHCO—, —CONH—, -0-, —C(═O)—, —CH═CH, —C≡C—, —NR5—; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or a stable monocyclic, bicyclic or tricyclic ring system; G is —O—, —S—, —CHR10—, —C(═O)—; J is —CH2—, or when G is CHR10 may also be —O— or —NH—; R10 is H, F, —CH3, —CH2NH2, —CH2OH; —OHR11 is H, F, —CH3, —CH2NH2, —CH2OH, —CH(OH)CH3, CH(NH3)CH3; or R10 and R11 together define an olefinic bond, or together form a —CH2-group, thereby defining a cis or trans cyclopropyl group; have utility in the prophylaxis or treatment of protozoal diseases such as malaria.